276 related articles for article (PubMed ID: 21911935)
1. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer.
Starczynowski DT; Lockwood WW; Deléhouzée S; Chari R; Wegrzyn J; Fuller M; Tsao MS; Lam S; Gazdar AF; Lam WL; Karsan A
J Clin Invest; 2011 Oct; 121(10):4095-105. PubMed ID: 21911935
[TBL] [Abstract][Full Text] [Related]
2. siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells.
He Z; Huang C; Lin G; Ye Y
Oncol Rep; 2016 Apr; 35(4):1933-40. PubMed ID: 26847475
[TBL] [Abstract][Full Text] [Related]
3. Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell.
Zhong L; Cao F; You Q
Tumour Biol; 2013 Feb; 34(1):231-9. PubMed ID: 23055197
[TBL] [Abstract][Full Text] [Related]
4. [Effect of TRAF6 Downregulation on Malignant Biological Behavior of
Lung Cancer Cell Lines].
Lin G; Huang C; Su G; Hu H; Xu H; Huang C
Zhongguo Fei Ai Za Zhi; 2015 Nov; 18(11):661-7. PubMed ID: 26582220
[TBL] [Abstract][Full Text] [Related]
5. MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression.
Pan D; Jiang C; Ma Z; Blonska M; You MJ; Lin X
Oncogene; 2016 Feb; 35(7):919-28. PubMed ID: 25982276
[TBL] [Abstract][Full Text] [Related]
6. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.
Bassères DS; Ebbs A; Levantini E; Baldwin AS
Cancer Res; 2010 May; 70(9):3537-46. PubMed ID: 20406971
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of NF-κB inducing kinase underlies constitutive NF-κB activation in lung cancer cells.
Saitoh Y; Martínez Bruyn VJ; Uota S; Hasegawa A; Yamamoto N; Imoto I; Inazawa J; Yamaoka S
Lung Cancer; 2010 Dec; 70(3):263-70. PubMed ID: 20338663
[TBL] [Abstract][Full Text] [Related]
8. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in
Mehta AK; Hua K; Whipple W; Nguyen MT; Liu CT; Haybaeck J; Weidhaas J; Settleman J; Singh A
Sci Signal; 2017 Sep; 10(496):. PubMed ID: 28900044
[No Abstract] [Full Text] [Related]
9. β-arrestin 2 negatively regulates lung cancer progression by inhibiting the TRAF6 signaling axis for NF-κB activation and autophagy induced by TLR3 and TLR4.
Kim JY; Shin JH; Kim MJ; Kang Y; Lee JS; Son J; Jeong SK; Kim D; Kim DH; Chun E; Lee KY
Cell Death Dis; 2023 Jul; 14(7):422. PubMed ID: 37443143
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions.
Tang X; Liu D; Shishodia S; Ozburn N; Behrens C; Lee JJ; Hong WK; Aggarwal BB; Wistuba II
Cancer; 2006 Dec; 107(11):2637-46. PubMed ID: 17078054
[TBL] [Abstract][Full Text] [Related]
11. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis.
Duran A; Linares JF; Galvez AS; Wikenheiser K; Flores JM; Diaz-Meco MT; Moscat J
Cancer Cell; 2008 Apr; 13(4):343-54. PubMed ID: 18394557
[TBL] [Abstract][Full Text] [Related]
12. A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.
Noels H; van Loo G; Hagens S; Broeckx V; Beyaert R; Marynen P; Baens M
J Biol Chem; 2007 Apr; 282(14):10180-9. PubMed ID: 17287209
[TBL] [Abstract][Full Text] [Related]
13. Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.
Kiefer PE; Wegmann B; Bacher M; Erbil C; Heidtmann H; Havemann K
J Cancer Res Clin Oncol; 1990; 116(1):29-37. PubMed ID: 1690210
[TBL] [Abstract][Full Text] [Related]
14. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567
[TBL] [Abstract][Full Text] [Related]
15. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
[TBL] [Abstract][Full Text] [Related]
16. Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.
Castillo SD; Angulo B; Suarez-Gauthier A; Melchor L; Medina PP; Sanchez-Verde L; Torres-Lanzas J; Pita G; Benitez J; Sanchez-Cespedes M
J Pathol; 2010 Sep; 222(1):89-98. PubMed ID: 20556744
[TBL] [Abstract][Full Text] [Related]
17. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.
Burns TF; Dobromilskaya I; Murphy SC; Gajula RP; Thiyagarajan S; Chatley SN; Aziz K; Cho YJ; Tran PT; Rudin CM
Mol Cancer Res; 2013 Apr; 11(4):329-38. PubMed ID: 23364532
[TBL] [Abstract][Full Text] [Related]
19. Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages.
Xu H; An H; Yu Y; Zhang M; Qi R; Cao X
J Biol Chem; 2003 Sep; 278(38):36334-40. PubMed ID: 12867418
[TBL] [Abstract][Full Text] [Related]
20. TRAF2 is an NF-κB-activating oncogene in epithelial cancers.
Shen RR; Zhou AY; Kim E; O'Connell JT; Hagerstrand D; Beroukhim R; Hahn WC
Oncogene; 2015 Jan; 34(2):209-16. PubMed ID: 24362534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
